Latest Clinical Development News

Radiopharm Theranostics has received FDA clearance to begin a Phase I clinical trial for RV-01, a novel radiopharmaceutical targeting the 4Ig isoform of B7-H3 in solid tumors, marking a significant step forward in cancer treatment innovation.

Neurizon Therapeutics has formally responded to the FDA's clinical hold on its lead ALS drug NUZ-001, submitting new animal safety data. The company aims to join the HEALEY ALS Platform Trial by late 2025, pending regulatory approval.

Dimerix has secured a significant licensing agreement with Amicus Therapeutics for its kidney disease drug candidate DMX-200 in the US, receiving a US$30 million upfront payment and advancing its Phase 3 trial with FDA endorsement of a key clinical endpoint.

Island Pharmaceuticals reported promising Phase 2a/b trial results for its dengue drug ISLA-101 and secured a strategic acquisition of the broad-spectrum antiviral Galidesivir, bolstering its pipeline and balance sheet.

Patrys Limited has announced a fully underwritten entitlement offer to raise approximately $1.77 million, aimed at funding ongoing research and development of its PAT-DX3 therapy and supporting working capital. The offer includes secondary options and shares, subject to shareholder approval, and will significantly expand the company's capital base.

Amplia Therapeutics has successfully raised A$25 million through an institutional placement and launched a A$2.5 million Share Purchase Plan to fund pivotal clinical trials of its lead drug narmafotinib. The capital injection positions the company to advance key pancreatic and ovarian cancer studies into 2027.

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart technology, reporting promising clinical results in Crohn’s disease and GVHD, alongside a $3.5 million capital raise to fuel next-stage development.

Tetratherix Limited has marked a pivotal quarter with a $25 million ASX listing, an exclusive licensing agreement with Bio Optix for ophthalmic devices, and progress on FDA regulatory submissions for its prostate spacer product.

Argenica Therapeutics has dosed the final patient in its Phase 2 trial for ARG-007 in acute ischaemic stroke, with topline results expected in Q3 2025. Meanwhile, the FDA has placed a clinical hold on its US trial application, introducing uncertainty for US development.

Race Oncology has safely treated the first patient with its RC220 drug alone and in combination with doxorubicin in a Phase 1 trial, while bolstering its clinical leadership and maintaining a strong cash position to fund operations through 2026.

InhaleRx Limited has secured key ethics approvals and initiated manufacturing for its inhaled drug candidates targeting breakthrough cancer pain and panic disorder, supported by a $38.5 million funding facility to accelerate development.

Prescient Therapeutics has extended the closing date of its Share Purchase Plan to July 25, 2025, responding to shareholder demand and reinforcing strong participation. The oncology-focused biotech also highlights upcoming clinical milestones and ongoing investor engagement.